Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Open in API
Filings indexed 422 across all filing types
Latest filing 2020-01-09 Director's Dealing
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-01-09 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 3, 2020, by Amplitude Healthcare Acquisition Corporation. The content includes the appointment of a new President (Mr. Vishal Kapoor), details of his employment agreement, and other related corporate governance matters such as forfeiture of founder shares and trading of units. There are no financial statements or detailed financial performance data included. The primary focus is on management changes and related agreements. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not an annual or quarterly report, nor is it an earnings release or regulatory filing of another type. Therefore, the correct classification is MANG with high confidence.
2020-01-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-01-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-01-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-01-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-01-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.